$0.03
(Market cap
$200 Mln
Recently Viewed
Clear AllMarket cap
$200 Mln
Revenue (TTM)
$9 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-51 Mln
ROE
-0.3 %
ROCE
-- %
Industry P/E
24.41
EV/EBITDA
-2.8
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
34,504,900
CFO
$-190.30 Mln
EBITDA
$-213.58 Mln
Net Profit
$-288.09 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
KemPharm (KMPH)
| 8.3 | -9.6 | -11.7 | 8.3 | -0.6 | -43.0 | -- |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
KemPharm (KMPH)
| -47.3 | -22.2 | 84.6 | -78.7 | -55.9 | 37.3 | -85.1 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
KemPharm (KMPH)
|
5.0 | 200.5 | 9.4 | -39.7 | -177.3 | -68.8 | -- | 1.7 |
| 12.8 | 3,993.9 | 2,323.3 | 44.1 | 12.3 | -- | 56.9 | 105.4 | |
| 41.0 | 5,233.8 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.4 | 14.1 | |
| 190.1 | 9,512.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 107.7 | |
| 74.9 | 14,206.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.4 | 4,944.9 | 761.4 | 99.7 | 7.3 | 15 | 56.2 | 7.6 | |
| 22.8 | 11,181.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.7 | |
| 236.2 | 4,634.3 | 268.1 | 124.5 | 60.0 | 13.5 | 37.7 | 4.6 | |
| 37.4 | 3,287.6 | 158.3 | -68.9 | -29.3 | -113 | -- | 73.8 | |
| 60.6 | 3,736.3 | 391.6 | -76.6 | -19.3 | -16.4 | -- | 8.2 |
Zevra Therapeutics, Inc., a rare disease therapeutics company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate... improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Zevra Therapeutics, Inc. has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. Read more
Exec. Chairman
Mr. Richard W. Pascoe
Exec. Chairman
Mr. Richard W. Pascoe
Headquarters
Celebration, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of KemPharm Inc (KMPH) is $4.97 (NASDAQ) as of 03-May-2023 09:30 EDT. KemPharm Inc (KMPH) has given a return of -0.57% in the last 3 years.
Since, TTM earnings of KemPharm Inc (KMPH) is negative, P/E ratio is not available.
The P/B ratio of KemPharm Inc (KMPH) is 1.69 times as on 03-May-2023, a 70 discount to its peers’ median range of 5.60 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of KemPharm Inc (KMPH) are Rs -- and Rs -- as of 27-Apr-2026.
KemPharm Inc (KMPH) has a market capitalisation of $ 200 Mln as on 03-May-2023. As per SEBI classification, it is a Small Cap company.
Before investing in KemPharm Inc (KMPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.